Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2010

01.06.2010 | Pancreatic Tumors

Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors

verfasst von: Massimo Falconi, MD, Alessandro Zerbi, MD, Stefano Crippa, MD, Gianpaolo Balzano, MD, Letizia Boninsegna, MD, Vanessa Capitanio, MD, Claudio Bassi, MD, Valerio Di Carlo, MD, Paolo Pederzoli, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Parenchyma-preserving resections (PPRs), including enucleation and middle pancreatectomy (MP), are accepted procedures for insulinomas, but their role in the treatment of nonfunctioning pancreatic endocrine tumors (NF-PETs) is debated. The aim of this study was to evaluate perioperative and long-term outcomes after PPRs for NF-PETs.

Methods

All patients who underwent PPRs for NF-PETs between 1990 and 2005 were included. Patients with multiple endocrine neoplasia type 1 were excluded.

Results

Overall, 50 patients (23 men, 27 women, median age 59 years) underwent 26 enucleations and 24 MP. A total of 58% of NF-PETs were incidentally discovered. Median size of the tumors was 13.5 mm with no preoperative suspicion of malignancy in all patients. Overall morbidity and pancreatic fistula rates were 58 and 50%, respectively. Reoperation rate was 4%, with no mortality. Postoperative complications were higher in the MP group. At pathology, there were 34 (68%) benign lesions, 13 (26%) neoplasms of uncertain behavior, and 3 (6%) well-differentiated carcinomas. Forty-one patients (82%) had tumors ≤2 cm in size. Only eight patients (16%) had at least one lymph node removed. After a median follow-up of 58 months, no patient died of disease. Overall, four patients (8%) experienced tumor recurrence after a mean of 68 months. The incidence of exocrine/endocrine insufficiency was 8%.

Conclusions

PPRs are generally safe and effective procedures for treating small NF-PETs. However, better selection criteria must be identified, and lymph node sampling should be performed routinely to avoid understaging. Long-term follow-up evaluation (>5 years) is of paramount importance given the possible risk of late recurrence.
Literatur
1.
2.
Zurück zum Zitat Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:327–31.CrossRefPubMed Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:327–31.CrossRefPubMed
3.
Zurück zum Zitat Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211.CrossRefPubMed Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211.CrossRefPubMed
4.
Zurück zum Zitat La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30–40.CrossRefPubMed La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30–40.CrossRefPubMed
5.
Zurück zum Zitat Dralle H, Krohn SL, Karges W, et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.CrossRefPubMed Dralle H, Krohn SL, Karges W, et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.CrossRefPubMed
6.
Zurück zum Zitat Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery. 1998;124:1056–61.CrossRefPubMed Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery. 1998;124:1056–61.CrossRefPubMed
7.
Zurück zum Zitat Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18:947–55.PubMed Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18:947–55.PubMed
8.
Zurück zum Zitat Lo CY, Lam KY, Kung AW, et al. Pancreatic insulinomas. A 15-year experience. Arch Surg. 1997;132:926–30.PubMed Lo CY, Lam KY, Kung AW, et al. Pancreatic insulinomas. A 15-year experience. Arch Surg. 1997;132:926–30.PubMed
9.
Zurück zum Zitat Crippa S, Bassi C, Salvia R, et al. Outcomes of pancreatic neoplasms enucleation. Br J Surg. 2007;94:1254–9.CrossRefPubMed Crippa S, Bassi C, Salvia R, et al. Outcomes of pancreatic neoplasms enucleation. Br J Surg. 2007;94:1254–9.CrossRefPubMed
10.
Zurück zum Zitat de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183–8.CrossRefPubMed de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183–8.CrossRefPubMed
11.
Zurück zum Zitat Trucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264–75.CrossRef Trucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264–75.CrossRef
12.
Zurück zum Zitat Müller MW, Friess H, Kleeff J, et al. Middle segmental pancreatic resection: an option to treat benign pancreatic body lesions. Ann Surg. 2006;244:909–18.CrossRefPubMed Müller MW, Friess H, Kleeff J, et al. Middle segmental pancreatic resection: an option to treat benign pancreatic body lesions. Ann Surg. 2006;244:909–18.CrossRefPubMed
13.
Zurück zum Zitat Falconi M, Mantovani W, Crippa S, et al. Pancreatic insufficiency after different resections for benign tumours. Br J Surg. 2008;95:85–91.CrossRefPubMed Falconi M, Mantovani W, Crippa S, et al. Pancreatic insufficiency after different resections for benign tumours. Br J Surg. 2008;95:85–91.CrossRefPubMed
14.
Zurück zum Zitat Crippa S, Bassi C, Warshaw AL, et al. Middle pancreatectomy: indications, operative and long-term results. Ann Surg. 2007;246:69–76.CrossRefPubMed Crippa S, Bassi C, Warshaw AL, et al. Middle pancreatectomy: indications, operative and long-term results. Ann Surg. 2007;246:69–76.CrossRefPubMed
15.
Zurück zum Zitat Aranha GV, Shoup M. Nonstandard pancreatic resections for unusual lesions. Am J Surg. 2005;189:223–8.CrossRefPubMed Aranha GV, Shoup M. Nonstandard pancreatic resections for unusual lesions. Am J Surg. 2005;189:223–8.CrossRefPubMed
16.
Zurück zum Zitat Balzano G, Zerbi A, Veronesi P, Cristallo M, Di Carlo V. Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg. 2003;20:506–10.CrossRefPubMed Balzano G, Zerbi A, Veronesi P, Cristallo M, Di Carlo V. Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg. 2003;20:506–10.CrossRefPubMed
17.
Zurück zum Zitat Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90:184–9.CrossRefPubMed Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90:184–9.CrossRefPubMed
18.
Zurück zum Zitat O’Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90:194–202.CrossRefPubMed O’Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90:194–202.CrossRefPubMed
19.
Zurück zum Zitat Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery. 2005;138:8–13.CrossRefPubMed Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery. 2005;138:8–13.CrossRefPubMed
20.
Zurück zum Zitat Heitz PU, Komminoth P, Perren, A et al. Pancreatic endocrine tumours. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Endocrine Organs. Lyon: IARC Press; 2004. Heitz PU, Komminoth P, Perren, A et al. Pancreatic endocrine tumours. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Endocrine Organs. Lyon: IARC Press; 2004.
21.
Zurück zum Zitat Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.CrossRefPubMed Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.CrossRefPubMed
22.
Zurück zum Zitat Pape UF, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.CrossRefPubMed Pape UF, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.CrossRefPubMed
23.
Zurück zum Zitat Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology. 2009;90:227–33.CrossRefPubMed Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology. 2009;90:227–33.CrossRefPubMed
24.
Zurück zum Zitat Iacono C, Bortolasi L, Serio G. Is there a place for central pancreatectomy in pancreatic surgery? J Gastrointestinal Surg. 1998;2:509–17.CrossRef Iacono C, Bortolasi L, Serio G. Is there a place for central pancreatectomy in pancreatic surgery? J Gastrointestinal Surg. 1998;2:509–17.CrossRef
25.
Zurück zum Zitat Warshaw AL, Rattner DW, Fernández-del Castillo C, Z’graggen K. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg. 1998;133:327–31.CrossRefPubMed Warshaw AL, Rattner DW, Fernández-del Castillo C, Z’graggen K. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg. 1998;133:327–31.CrossRefPubMed
26.
Zurück zum Zitat Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6:419–28.CrossRefPubMed Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6:419–28.CrossRefPubMed
27.
Zurück zum Zitat Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244:61–70.CrossRefPubMed Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244:61–70.CrossRefPubMed
28.
Zurück zum Zitat Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or =2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–62.CrossRefPubMed Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or =2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–62.CrossRefPubMed
29.
Zurück zum Zitat Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson NW. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery. 2009;146:801–6.CrossRefPubMed Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson NW. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery. 2009;146:801–6.CrossRefPubMed
30.
Zurück zum Zitat Balzano G, Zerbi A, Capretti G, et al. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg. 2008;95:357–62.CrossRefPubMed Balzano G, Zerbi A, Capretti G, et al. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg. 2008;95:357–62.CrossRefPubMed
31.
Zurück zum Zitat Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–27.CrossRefPubMed Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–27.CrossRefPubMed
32.
Zurück zum Zitat Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.CrossRefPubMed Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.CrossRefPubMed
33.
Zurück zum Zitat Vilar E, Salazar R, Pérez-García J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221–32.CrossRefPubMed Vilar E, Salazar R, Pérez-García J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221–32.CrossRefPubMed
34.
Zurück zum Zitat Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609–15.CrossRefPubMed Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609–15.CrossRefPubMed
35.
Zurück zum Zitat Reber HA. Middle pancreatectomy: why I rarely do it. J Gastrointest Surg. 2007;11:726–9.CrossRef Reber HA. Middle pancreatectomy: why I rarely do it. J Gastrointest Surg. 2007;11:726–9.CrossRef
Metadaten
Titel
Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors
verfasst von
Massimo Falconi, MD
Alessandro Zerbi, MD
Stefano Crippa, MD
Gianpaolo Balzano, MD
Letizia Boninsegna, MD
Vanessa Capitanio, MD
Claudio Bassi, MD
Valerio Di Carlo, MD
Paolo Pederzoli, MD
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0949-8

Weitere Artikel der Ausgabe 6/2010

Annals of Surgical Oncology 6/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.